Scarica l'app Stockscreener
20.40
8.51%
1.60
Dopo l'orario di chiusura:
20.17
-0.23
-1.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSRPT - FinancialContent
Prasad Returns, Delany Departs, Lilly’s Weight Loss Pill Disappoints and Sarepta’s Fallout Continues - BioSpace
Sarepta Provides New Elevidys Safety Data, Reveals Zero Ambulatory Deaths - BioSpace
2025-08-12 | Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Contact Levi & Korsinsky Before August 25, 2025 to Join Class Action | NDAQ:SRPT | Press Release - Stockhouse
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside - MarketBeat
Sarepta details Elevidys’ liver toxicity data and plans for safety study - Endpoints News
Caught In Sarepta ‘Downdraft,’ Arrowhead Becomes RNAi Knight in Shining Armor - BioSpace
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - FinancialContent
Levi & Korsinsky Urges Sarepta Therapeutics, Inc. (SRPT) Shareholders to Act Before Lead Plaintiff Deadline August 25, 2025 - ACCESS Newswire
SAREPTA (SRPT) LAWSUIT ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Vinay Prasad returns to role as top vaccine regulator at FDA days after leaving US agency - Reuters
August 25, 2025 Deadline Approaching: Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)Contact Levi & Korsinsky - Newsfile
SRPT COURT REMINDER: Sarepta Therapeutics, Inc. was Sued for Fraud -- Investors are Notified to Contact BFA Law by August 25 Deadline - ACCESS Newswire
Sarepta Therapeutics, Inc. Securities Fraud Class Action - GlobeNewswire
Sarepta Therapeutics (SRPT) Declines Again On EMA - GlobeNewswire
Sarepta stock rises as Jefferies reiterates Buy rating after Elevidys shipments resume - Investing.com Canada
Sarepta stock rating upgraded to Buy by Freedom Broker on ELEVIDYS supply resumption - Investing.com Canada
A mild market reaction for companies on Prasad’s return - BioWorld MedTech
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Benzinga
SRPT LAWSUIT ALERT: The Gross Law Firm Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Unexpected Shifts in the Gene Transfer Technologies Market - openPR.com
SRPT COURT NOTICE: Sarepta Therapeutics Investors may have - GlobeNewswire
Vinay Prasad’s Return to FDA Sends Biotech Shares Tumbling - Bloomberg.com
Vor Bio lures Sarepta exec to be its CCO - The Pharma Letter
SRPT Lawsuit Alert! Class Action Lawsuit Against Sarepta Therapeutics - TipRanks
Biotech sector slips amid reported return of ousted FDA official - MSN
Biotech sector slips amid reported return of ousted FDA official (SRPT:NASDAQ) - Seeking Alpha
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - Defense World
Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light - BioSpace
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) InvestorsLead Plaintiff Deadline on August 25, 2025 - ACCESS Newswire
Shareholders of Sarepta Therapeutics, Inc. (SRPT): Protect Your Rights Before August 25, 2025Contact Levi & Korsinsky - ACCESS Newswire
SRPT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SRPT - GlobeNewswire Inc.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - TradingView
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $19.00 at The Goldman Sachs Group - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $19.00 - Defense World
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline - ACCESS Newswire
2025-08-09 | Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline | NDAQ:SRPT | Press Release - Stockhouse
SRPT INVESTOR NOTICE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - PR Newswire
Shareholders that lost money on Sarepta Therapeutics, - GlobeNewswire
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar
SRPT ALERT: BFA Law Urges Sarepta Therapeutics, Inc. Investors with Losses to Contact the Firm before the Imminent August 25 Court Deadline - Newsfile
SRPT Deadline: SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit - Barchart.com
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com
Securities Lawsuit Alert: Sarepta Therapeutics, Inc. (SRPT) InvestorsContact Levi & Korsinsky Before August 25, 2025 - Barchart.com
Duchenne Muscular Dystrophy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics - Barchart.com
Elevidys sales weaken; Neumora gets into obesity - BioPharma Dive
As gene therapies falter on the market, this biopharma is aiming to defy the odds - PharmaVoice
Vor Bio hires former Sarepta exec to lead commercial strategy; Mallinckrodt poaches CFO from Incyte - Endpoints News
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Sarepta soars as revenue beats estimates on Elevidys milestone - The Boston Globe
Sarepta Shares Surge 10.46% on Record Q2 Revenue Despite Safety Scrutiny Trading Volume Ranks 407th - AInvest
Sarepta Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Class Action Filed Against Sarepta Therapeutics, Inc. - GlobeNewswire
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT)August 25, 2025 Deadline to Join – Contact The Gross Law Firm - Morningstar
SRPT SHAREHOLDERS: Sarepta Therapeutics Stock Drop Triggers - GlobeNewswire
Sarepta’s Stock Surges as FDA Lifts Elevidys Hold - StocksToTrade
Sarepta Gets A Price Target Hike From Wells Fargo: Retail Highlights Consistent Demand For Elevidys - Stocktwits
Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Contact Levi & Korsinsky to Join Class Action Before August 25, 2025 - ACCESS Newswire
Eli Lilly’s key obesity pill falls short of rivals, but the company still beat on earnings - statnews.com
Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries - Yahoo Finance
Cautious Outlook on Sarepta Therapeutics Amid Financial Strain and ELEVIDYS Challenges - TipRanks
Despite Safety Drama, Sarepta Beats Q2 Estimates—But No Thanks to Elevidys Sales - BioSpace
Sarepta Therapeutics stock price target raised to $50 by Wells Fargo - Investing.com
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):